risedronic acid has been researched along with Bone Diseases, Metabolic in 57 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Bone Diseases, Metabolic: Diseases that affect the METABOLIC PROCESSES of BONE TISSUE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Anastrozole has been shown to prevent breast cancer in postmenopausal women at high risk of the disease, but has been associated with substantial accelerated loss of bone mineral density (BMD) and increased fractures." | 9.30 | Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. ( Blake, GM; Coleman, RE; Cuzick, J; Eastell, R; Patel, R; Sestak, I, 2019) |
| "In patients with mild or severe osteopenia or osteoporosis, treated with A + R, no age effect was observed for LS or HP (p = 0." | 5.38 | Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012) |
| "Anastrozole has been shown to prevent breast cancer in postmenopausal women at high risk of the disease, but has been associated with substantial accelerated loss of bone mineral density (BMD) and increased fractures." | 5.30 | Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. ( Blake, GM; Coleman, RE; Cuzick, J; Eastell, R; Patel, R; Sestak, I, 2019) |
| "We have found 11 cases of BRONJ in our hospital: 4 women taking oral alendronate or risendronate for osteoporosis and 7 cancer patients treated with intravenous zolendronic acid." | 4.88 | [Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces]. ( Arranz Caso, JA; Dominguez-Mompello, JL; Flores Ballester, E; López Pizarro, V; Ngo Pombe, S; Restoy Lozano, A, 2012) |
| "Patients were eligible for inclusion if they had osteoporosis or osteopenia and demonstrated a decline in BMD during the preceding year while taking stable doses of alendronate or risedronate, plus supplemental calcium and vitamin D." | 3.74 | Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients. ( Adams, JS; Geller, JL; Hu, B; Mirocha, J; Reed, S, 2008) |
| " The subjects' bone mineral densities (BMDs), bone turnover markers (P1NP and β-CTX), new vertebral fractures, and adverse events were assessed at baseline and during the treatments." | 2.80 | The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data. ( Chen, DC; Fu, WZ; Gu, JM; He, JW; Hu, WW; Hu, YQ; Jin, XL; Lin, H; Liu, YJ; Tang, H; Wang, C; Wang, L; Xia, WB; Yue, H; Zhang, H; Zhang, ZL, 2015) |
| "Patients with Crohn's disease have an increased frequency of osteopenia and osteoporosis." | 2.77 | Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial. ( Fedorak, RN; McQueen, B; Siffledeen, J; Siminoski, K; Soo, I, 2012) |
| "Six postmenopausal women with diagnosed osteopenia/osteoporosis received a single oral dose of 100 nCi 41Ca for skeleton labeling." | 2.73 | Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass. ( Denk, E; Fattinger, K; Häuselmann, HJ; Hillegonds, D; Hurrell, RF; Kraenzlin, M; Vogel, J; Walczyk, T, 2007) |
| " A random-effects model within a Bayesian framework was applied to compare treatment effects as standardized mean difference (SMD) with their corresponding 95% credible interval (CrI), while odds ratio (OR) was applied to compare adverse events with 95% CrI." | 2.55 | Efficacy and safety of medical therapy for low bone mineral density in patients with Crohn disease: A systematic review with network meta-analysis. ( Chen, H; Ma, H; Ma, J; Wang, P; Zhang, H; Zhang, Y; Zhao, X; Zhou, C; Zhu, Y, 2017) |
| "Osteopenia is a progressive condition that places patients at risk for increased morbidity and mortality if untreated." | 2.42 | Identifying the osteopenic patient and preventing worsening of the disease. ( Derman, R, 2003) |
| "Menatetrenone has less positive effects on BMD but reduces the risk of fracture by improving bone quality." | 1.56 | Effects of the combined administration of risedronate and menatetrenone on bone loss induced by tacrolimus in rats. ( Furukawa, M; Izumo, N; Kanda, J; Shimakura, T; Takahashi, HE; Wakabayashi, H; Yamamoto, N, 2020) |
| "In patients with mild or severe osteopenia or osteoporosis, treated with A + R, no age effect was observed for LS or HP (p = 0." | 1.38 | Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012) |
| "OASIS-/- mice exhibit severe osteopenia involving a decrease in type I collagen in the bone matrix and a dysfunction of osteoblasts, which show abnormal expansion of the rough ER." | 1.36 | Effects of the bisphosphonate risedronate on osteopenia in OASIS-deficient mice. ( Hino, S; Imaizumi, K; Murakami, T; Ochiai, K; Saito, A; Sekiya, H; Tsumagari, K, 2010) |
| "A total of 196 consecutive patients treated for distal radius fractures were included in this study." | 1.35 | Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. ( Ayogu, N; Bouxsein, ML; Chacko, AT; Rozental, TD; Vazquez, MA, 2009) |
| "Postmenopausal women with osteopenia, defined as femoral neck T-score between -1 and -2." | 1.35 | Effects of risedronate on fracture risk in postmenopausal women with osteopenia. ( Barton, IP; Grauer, A; McClung, MR; Simon, JA; Siris, ES, 2008) |
| "The purposes of the present study were to differentiate the effects of pre-surgery treatment with risedronate and post-surgery treatment with a reduced dosing frequency of risedronate on trabecular bone loss in ovariectomized rats and to determine whether post-surgery treatment with a reduced dosing frequency of risedronate would have a beneficial effect on trabecular bone loss after pre-surgery treatment with risedronate by means of bone histomorphometric analysis." | 1.33 | Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats. ( Iwamoto, J; Sato, Y; Shen, CL; Takeda, T; Yeh, JK, 2006) |
| "The purpose of the present study was to examine the effect of pretreatment with risedronate and/or vitamin K2 and treatment continuation with reduced dosing frequency of the drugs on the early cancellous bone loss induced by ovariectomy (OVX) in rats." | 1.33 | Beneficial effect of pretreatment and treatment continuation with risedronate and vitamin K2 on cancellous bone loss after ovariectomy in rats: a bone histomorphometry study. ( Iwamoto, J; Sato, Y; Shen, CL; Takeda, T; Yeh, JK, 2006) |
| " These findings indicated that the long-term administration of PGE2 alone cannot maintain or continue to add bone mass in ovx rats but that co-treatment of a PGE2 with an anti-resorptive or activation agent can resist the influence of the mechanostat induced bone loss as well as continue to add bone." | 1.29 | Co-treatment of PGE2 and risedronate is better than PGE2 alone in the long-term treatment of ovariectomized-induced osteopenic rats. ( Chen, YY; Ijiri, K; Jee, WS; Ke, HZ; Ma, Y, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (17.54) | 18.2507 |
| 2000's | 21 (36.84) | 29.6817 |
| 2010's | 24 (42.11) | 24.3611 |
| 2020's | 2 (3.51) | 2.80 |
| Authors | Studies |
|---|---|
| Tutaworn, T | 1 |
| Nieves, JW | 1 |
| Wang, Z | 1 |
| Levin, JE | 1 |
| Yoo, JE | 1 |
| Lane, JM | 1 |
| Kanda, J | 1 |
| Furukawa, M | 1 |
| Izumo, N | 1 |
| Shimakura, T | 1 |
| Yamamoto, N | 1 |
| Takahashi, HE | 1 |
| Wakabayashi, H | 1 |
| Lange, U | 1 |
| Classen, K | 1 |
| Müller-Ladner, U | 1 |
| Richter, M | 1 |
| Sestak, I | 1 |
| Blake, GM | 1 |
| Patel, R | 1 |
| Coleman, RE | 1 |
| Cuzick, J | 1 |
| Eastell, R | 1 |
| Damm, DD | 1 |
| Jones, DM | 1 |
| van Bodegraven, AA | 1 |
| Bravenboer, N | 1 |
| Witte, BI | 1 |
| Dijkstra, G | 1 |
| van der Woude, CJ | 1 |
| Stokkers, PC | 1 |
| Russel, MG | 1 |
| Oldenburg, B | 1 |
| Pierik, M | 1 |
| Roos, JC | 1 |
| van Hogezand, RA | 1 |
| Dik, VK | 1 |
| Oostlander, AE | 1 |
| Netelenbos, JC | 1 |
| van de Langerijt, L | 1 |
| Hommes, DW | 1 |
| Lips, P | 1 |
| Bernstein, CN | 1 |
| Targownik, LE | 1 |
| Leslie, WD | 1 |
| Pepe, J | 1 |
| Isidori, AM | 1 |
| Falciano, M | 1 |
| Iaiani, G | 1 |
| Salotti, A | 1 |
| Diacinti, D | 1 |
| Del Fiacco, R | 1 |
| Sbardella, E | 1 |
| Cipriani, C | 1 |
| Piemonte, S | 1 |
| Raimo, O | 1 |
| Biondi, P | 1 |
| Biamonte, F | 1 |
| Lenzi, A | 1 |
| Minisola, S | 1 |
| Iwamoto, J | 6 |
| Seki, A | 4 |
| Gu, JM | 1 |
| Wang, L | 1 |
| Lin, H | 1 |
| Chen, DC | 1 |
| Tang, H | 1 |
| Jin, XL | 1 |
| Xia, WB | 1 |
| Hu, YQ | 1 |
| Fu, WZ | 1 |
| He, JW | 1 |
| Zhang, H | 2 |
| Wang, C | 1 |
| Yue, H | 1 |
| Hu, WW | 1 |
| Liu, YJ | 1 |
| Zhang, ZL | 1 |
| Sugie-Oya, A | 1 |
| Takakura, A | 1 |
| Takao-Kawabata, R | 1 |
| Sano, H | 1 |
| Shimazu, Y | 1 |
| Isogai, Y | 1 |
| Yamaguchi, A | 1 |
| Ishizuya, T | 1 |
| Cheung, MS | 1 |
| Paliologo, T | 1 |
| Shimano, RC | 1 |
| Shimano, AC | 1 |
| Macedo, AP | 1 |
| Falcai, MJ | 1 |
| Issa, JPM | 1 |
| Bhavsar, NV | 1 |
| Trivedi, SR | 1 |
| Dulani, K | 1 |
| Brahmbhatt, N | 1 |
| Shah, S | 1 |
| Chaudhri, D | 1 |
| Veszelyné Kotán, E | 1 |
| Mészaros, Á | 1 |
| Zhao, X | 1 |
| Zhou, C | 1 |
| Chen, H | 1 |
| Ma, J | 1 |
| Zhu, Y | 1 |
| Wang, P | 1 |
| Zhang, Y | 1 |
| Ma, H | 1 |
| Mahl, CR | 1 |
| Fontanella, V | 1 |
| Hines, SL | 1 |
| Mincey, BA | 1 |
| Sloan, JA | 1 |
| Thomas, SP | 1 |
| Chottiner, E | 1 |
| Loprinzi, CL | 1 |
| Carlson, MD | 1 |
| Atherton, PJ | 1 |
| Salim, M | 1 |
| Perez, EA | 1 |
| Rozental, TD | 1 |
| Vazquez, MA | 1 |
| Chacko, AT | 1 |
| Ayogu, N | 1 |
| Bouxsein, ML | 1 |
| Sekiya, H | 1 |
| Murakami, T | 1 |
| Saito, A | 1 |
| Hino, S | 1 |
| Tsumagari, K | 1 |
| Ochiai, K | 1 |
| Imaizumi, K | 1 |
| Migliorati, CA | 1 |
| Mattos, K | 1 |
| Palazzolo, MJ | 1 |
| Fitzpatrick, SG | 1 |
| Stavropoulos, MF | 1 |
| Bowers, LM | 1 |
| Neuman, AN | 1 |
| Hinkson, DW | 1 |
| Green, JG | 1 |
| Bhattacharyya, I | 1 |
| Cohen, DM | 1 |
| Yurci, A | 1 |
| Kalkan, AO | 1 |
| Ozbakir, O | 1 |
| Karaman, A | 1 |
| Torun, E | 1 |
| Kula, M | 1 |
| Baskol, M | 1 |
| Gursoy, S | 1 |
| Yucesoy, M | 1 |
| Bayram, F | 1 |
| Soo, I | 1 |
| Siffledeen, J | 1 |
| Siminoski, K | 1 |
| McQueen, B | 1 |
| Fedorak, RN | 1 |
| Namazi, H | 1 |
| Markopoulos, C | 1 |
| Tzoracoleftherakis, E | 1 |
| Koukouras, D | 1 |
| Venizelos, B | 1 |
| Zobolas, V | 1 |
| Misitzis, J | 1 |
| Xepapadakis, G | 1 |
| Gogas, H | 1 |
| Davey, DA | 1 |
| Coco, M | 1 |
| Pullman, J | 1 |
| Cohen, HW | 1 |
| Lee, S | 1 |
| Shapiro, C | 1 |
| Solorzano, C | 1 |
| Greenstein, S | 1 |
| Glicklich, D | 1 |
| Arranz Caso, JA | 1 |
| Flores Ballester, E | 1 |
| Ngo Pombe, S | 1 |
| López Pizarro, V | 1 |
| Dominguez-Mompello, JL | 1 |
| Restoy Lozano, A | 1 |
| Derman, R | 1 |
| Hershman, D | 1 |
| Narayanan, R | 1 |
| Tanriverdi, HA | 1 |
| Barut, A | 1 |
| Sarikaya, S | 1 |
| Majima, T | 1 |
| Komatsu, Y | 1 |
| Doi, K | 1 |
| Takagi, C | 1 |
| Shigemoto, M | 1 |
| Fukao, A | 1 |
| Morimoto, T | 1 |
| Corners, J | 1 |
| Nakao, K | 1 |
| Takeda, T | 5 |
| Sato, Y | 5 |
| Yamada, H | 3 |
| Shen, CL | 4 |
| Yeh, JK | 5 |
| Kikuchi, Y | 1 |
| Imakiire, T | 1 |
| Yamada, M | 1 |
| Saigusa, T | 1 |
| Hyodo, T | 1 |
| Kushiyama, T | 1 |
| Higashi, K | 1 |
| Hyodo, N | 1 |
| Yamamoto, K | 1 |
| Suzuki, S | 1 |
| Miura, S | 1 |
| Torregrosa, JV | 1 |
| Fuster, D | 1 |
| Pedroso, S | 1 |
| Diekmann, F | 1 |
| Campistol, JM | 1 |
| Rubí, S | 1 |
| Oppenheimer, F | 1 |
| Denk, E | 1 |
| Hillegonds, D | 1 |
| Hurrell, RF | 1 |
| Vogel, J | 1 |
| Fattinger, K | 1 |
| Häuselmann, HJ | 1 |
| Kraenzlin, M | 1 |
| Walczyk, T | 1 |
| Siris, ES | 1 |
| Simon, JA | 1 |
| Barton, IP | 1 |
| McClung, MR | 1 |
| Grauer, A | 1 |
| Libouban, H | 1 |
| Blouin, S | 1 |
| Moreau, MF | 1 |
| Baslé, MF | 1 |
| Audran, M | 1 |
| Chappard, D | 1 |
| Dane, C | 1 |
| Dane, B | 1 |
| Cetin, A | 1 |
| Erginbas, M | 1 |
| Geller, JL | 1 |
| Hu, B | 1 |
| Reed, S | 1 |
| Mirocha, J | 1 |
| Adams, JS | 1 |
| Li, M | 1 |
| Mosekilde, L | 4 |
| Søgaard, CH | 2 |
| Thomsen, JS | 3 |
| Wronski, TJ | 4 |
| Boyce, RW | 1 |
| Paddock, CL | 1 |
| Gleason, JR | 1 |
| Sletsema, WK | 1 |
| Eriksen, EF | 1 |
| Danielsen, CC | 1 |
| McOsker, JE | 3 |
| Dann, LM | 1 |
| Qi, H | 1 |
| Yen, CF | 1 |
| Ma, Y | 2 |
| Chen, YY | 1 |
| Jee, WS | 4 |
| Ke, HZ | 3 |
| Ijiri, K | 1 |
| Liang, HH | 1 |
| Ma, YF | 1 |
| Pan, Z | 1 |
| Setterberg, RB | 1 |
| Li, XJ | 2 |
| Chen, Y | 1 |
| Gasser, J | 1 |
| Kimmel, DB | 3 |
| Goa, KL | 1 |
| Balfour, JA | 1 |
| Iwaniec, UT | 2 |
| Samnegård, E | 1 |
| Cullen, DM | 1 |
| Mitova-Caneva, NG | 1 |
| Tang, LY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Randomized, Placebo-Controlled, Double-Blind Trial Of Risedronate (Actonel) For Prevention Of Bone Loss In Premenopausal Women Undergoing Chemotherapy For Primary Breast Carcinoma[NCT00054418] | Phase 3 | 216 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant[NCT00266708] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| A Comparative Study of Calcium Metabolism in Caucasian and Asian Postmenopausal Women of Chinese Descent and the Use of Strontium as a Qualitative Marker of Calcium Metabolism in Humans[NCT02565602] | 10 participants (Actual) | Interventional | 2014-02-28 | Completed | |||
| Using Ca-41 Methodology to Assess the Impact of Different Vitamin D Supplementation Levels on Postmenopausal Bone Health[NCT01053481] | Early Phase 1 | 25 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Randomized Control Trial of Bone Loading Exercises Versus Risedronate on Bone Health in Post-Menopausal Women[NCT02186600] | Phase 3 | 276 participants (Actual) | Interventional | 2015-02-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Bone mineral density (BMD) of the distal third of the nondialysis access forearm were measured using the Hologic 4500 QDC scanner. (NCT00266708)
Timeframe: month 12 of the treatment
| Intervention | gm/cm^2 (Mean) |
|---|---|
| Risedronate | 0.55 |
| Placebo | 0.58 |
Bone mineral density (BMD) of the distal third of the nondialysis access forearm were measured using the Hologic 4500 QDC scanner. (NCT00266708)
Timeframe: month 6 of the treatment
| Intervention | gm/cm^2 (Mean) |
|---|---|
| Risedronate | 0.57 |
| Placebo | 0.58 |
Bone Mineral Density (BMD) measurements were of the vertebral spine (L1-L4) measured using same Hologic 4500 QDC scanner. (NCT00266708)
Timeframe: month 12 of treatment
| Intervention | gm/cm^2 (Mean) |
|---|---|
| Risedronate | 1.00 |
| Placebo | 1.00 |
Bone Mineral Density (BMD) measurements were of the vertebral spine (L1-L4) measured using the Hologic 4500 QDC scanner. (NCT00266708)
Timeframe: month 6 of the treatment
| Intervention | gm/cm^2 (Mean) |
|---|---|
| Risedronate | 0.98 |
| Placebo | 0.97 |
Bone mineral density (BMD) of the total hip were measured using the Hologic 4500 QDC scanner. (NCT00266708)
Timeframe: month 12 of the treatment
| Intervention | gm/cm^2 (Mean) |
|---|---|
| Risedronate | 0.91 |
| Placebo | 0.87 |
Bone mineral density (BMD) of the total hip were measured using the Hologic 4500 QDC scanner. (NCT00266708)
Timeframe: month 6 of the treatment
| Intervention | gm/cm^2 (Mean) |
|---|---|
| Risedronate | 0.88 |
| Placebo | 0.86 |
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoblasts (OB) are cells that make bones by producing a matrix that becomes mineralized. Bone formation rate (BFR) indicates how much of the bone is actively mineralizing; it is determined by the number of active OB and the average work of each OB. (NCT00266708)
Timeframe: Baseline and month 12 of the treatment
| Intervention | micron/day (Mean) | |
|---|---|---|
| Baseline | month 12 | |
| Placebo | 0.04 | 0.05 |
| Risedronate | 0.02 | 0.10 |
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Bone mineralization is the process of laying down minerals on the matrix of the bone, with calcium and phosphorus as the most abundant minerals. Mineralized Bone Volume (MdV) is the percentage of mineralized bone tissue. (NCT00266708)
Timeframe: Baseline and month 12 of the treatment
| Intervention | percent (Mean) | |
|---|---|---|
| Baseline | month 12 | |
| Placebo | 1.3 | 1.0 |
| Risedronate | 1.2 | 1.2 |
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue. The reported values indicates the Osteoid Volume (OV), the volume of bone that consists of unmineralized bone. (NCT00266708)
Timeframe: Baseline and month 12 of the treatment
| Intervention | micron^3 (Mean) | |
|---|---|---|
| Baseline | month 12 | |
| Placebo | 0.06 | 0.03 |
| Risedronate | 0.06 | 0.10 |
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Percent Bone Volume is the percentage of total volume occupied by calcified bone. Percent Bone volume is calculated as Bone Volume (BV) divided by Tissue Volume (TV), where TV is bone plus marrow. (NCT00266708)
Timeframe: Baseline and month 12 of the treatment
| Intervention | percent (Mean) | |
|---|---|---|
| Baseline | month 12 | |
| Placebo | 13.3 | 9.7 |
| Risedronate | 10.7 | 11.3 |
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoclasts (OC) are cells responsible for bone resorption, which is the breaking down of bones. Osteoclasts make and secret digestive enzymes tha break up or dissolve the bone tissue. An eroded surface (ES) is the surface of the lacuna ( a cavity or depression in the bone) generated by an active OC. The reported values indicate the percent of eroded surface relative to bone surface (BS). (NCT00266708)
Timeframe: Baseline and month 12 of the treatment
| Intervention | percent (Mean) | |
|---|---|---|
| Baseline | month 12 | |
| Placebo | 1.36 | 0.82 |
| Risedronate | 9 | 2.7 |
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Percent Mineralized Bone Volume is the percentage of Bone Volume consisting of mineralized bone. Percent Mineralized Bone Volume is calculated as Mineralized Bone Volume (MdV) divided by Bone Volume (BV). (NCT00266708)
Timeframe: Baseline and month 12 of the treatment
| Intervention | percent (Mean) | |
|---|---|---|
| Baseline | month 12 | |
| Placebo | 95 | 96 |
| Risedronate | 95 | 92 |
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoblasts (OB) are cells that make bones by producing a matrix that becomes mineralized. Bone mass is a balance between the osteoblasts (OB) that form the bone and cells called osteoclasts (OC) that break down the bone. The reported values indicate the percent of bone surface (BS) that is made up of osteoblasts (OB). (NCT00266708)
Timeframe: Baseline and month 12 of the treatment
| Intervention | percent (Mean) | |
|---|---|---|
| Baseline | month 12 | |
| Placebo | 1.3 | 0.75 |
| Risedronate | 2.3 | 1.23 |
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoclasts (OC) are cells responsible for bone resorption, which is the breaking down of bones. Osteoclasts make and secrete digestive enzymes that break up or dissolve the bone tissue. Bone mass is a balance between the osteoblasts (OB) cells that form the bone and the osteoclasts (OC) cells that break down the bone. The reported values indicate the percent of bone surface (BS) that consists of osteoclasts (OC). (NCT00266708)
Timeframe: Baseline and month 12 of the treatment
| Intervention | percent (Mean) | |
|---|---|---|
| Baseline | month 12 | |
| Placebo | 0.97 | 0.68 |
| Risedronate | 1.5 | 0.28 |
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue. The reported values indicates the percent of bone surface that consists of unmineralized bone. It is equal to Osteoid Surface (OS) divided by Bone Surface (BS). (NCT00266708)
Timeframe: Baseline and month 12 of the treatment
| Intervention | percent (Mean) | |
|---|---|---|
| Baseline | month 12 | |
| Placebo | 15 | 14 |
| Risedronate | 23 | 24 |
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue. The reported values indicates the percent of a given volume of bone that consists of unmineralized bone. It is equal to Osteoid Volume (OV) divided by Bone Volume (BV). (NCT00266708)
Timeframe: Baseline and month 12 of the treatment
| Intervention | percent (Mean) | |
|---|---|---|
| Baseline | month 12 | |
| Placebo | 4.6 | 4.9 |
| Risedronate | 4.1 | 8.7 |
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue. The reported values indicates the percent of a given volume of tissue (bone + marrow) that consists of unmineralized bone. It is equal to Osteoid Volume (OV) divided by Tissue Volume (TV). (NCT00266708)
Timeframe: Baseline and month 12 of the treatment
| Intervention | percent (Mean) | |
|---|---|---|
| Baseline | month 12 | |
| Placebo | 0.58 | 0.51 |
| Risedronate | 0.49 | 0.90 |
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy. The ends of certain bones, known as cancellous bones, are actually not solid but are full of holes that are connected to each other by thin rods and plates of bone tissue known as trabeculae. Trabeculae of bone provide structural support to the spongy bone found at the ends of long bones. Trabeculae Trabecular Thickness (TbTh), a structural parameter, is the distance across individual trabecula. (NCT00266708)
Timeframe: Baseline and month 12 of the treatment
| Intervention | micron (Mean) | |
|---|---|---|
| Baseline | month 12 | |
| Placebo | 90.9 | 62.2 |
| Risedronate | 72.6 | 72.1 |
Bone mineral density is the gold standard for diagnosis of low bone mass and osteoporosis and will be measured at the spine using Dual Energy X-ray Absorptiometry (DXA). (NCT02186600)
Timeframe: Baseline,6, and 12 months
| Intervention | g/cm^2 (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 0.889 | .887 | 0.885 |
| Exercise | 0.886 | .878 | 0.885 |
| Risedronate | 0.892 | .907 | 0.911 |
"Change in Bone Strength Index (BSI) of the distal tibia based on randomization to Control, Risedronate, or Exercise group.~BSI (mg2/mm4) at the 4% tibial site will be measured using peripheral quantitative computed tomography (pQCT)." (NCT02186600)
Timeframe: Baseline, 6, and 12 months
| Intervention | mg^2/mm^4 (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 2098.7 | 2105.89 | 2107.2 |
| Exercise | 2001 | 1987.42 | 2009.2 |
| Risedronate | 1993.3 | 1997.32 | 2014.2 |
Bone turnover is the process of removing old bone (resorption by osteoclasts) and replacing it with new bone (formation by osteoblasts). Menopause results in a brief period (~5 years) of accelerated turnover with resorption far exceeding formation. In this study, resorption will be measured by Serum NTx. (NCT02186600)
Timeframe: Baseline, 6, 12 months
| Intervention | nanoMolar Bone Collagen Equivalents/L (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 13.99 | 12.16 | 12.36 |
| Exercise | 15.03 | 13.36 | 13.92 |
| Risedronate | 14.31 | 10.30 | 11.42 |
7 reviews available for risedronic acid and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Drugs Used in Paediatric Bone and Calcium Disorders.
Topics: Acetazolamide; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitoni | 2015 |
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic A | 2016 |
Efficacy and safety of medical therapy for low bone mineral density in patients with Crohn disease: A systematic review with network meta-analysis.
Topics: Alendronate; Bayes Theorem; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic | 2017 |
[Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces].
Topics: Actinomyces; Actinomycosis; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Bisphosphon | 2012 |
Identifying the osteopenic patient and preventing worsening of the disease.
Topics: Alendronate; Body Mass Index; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Calcitonin; Es | 2003 |
Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.
Topics: Absorptiometry, Photon; Alendronate; Antineoplastic Agents; Bone Density; Bone Density Conservation | 2004 |
Risedronate.
Topics: Animals; Biological Availability; Bone Density; Bone Diseases, Metabolic; Bone Neoplasms; Bone Resor | 1998 |
13 trials available for risedronic acid and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia.
Topics: Anastrozole; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Breast Neoplasms; Female; Frac | 2019 |
Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabo | 2014 |
The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data.
Topics: Aged; Asian People; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; China; | 2015 |
Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer.
Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neo | 2009 |
Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease.
Topics: Absorptiometry, Photon; Adult; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agen | 2011 |
Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabo | 2012 |
Effect of risedronate on bone in renal transplant recipients.
Topics: Adult; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Me | 2012 |
Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women.
Topics: Atorvastatin; Bone Density; Bone Diseases, Metabolic; Cholesterol; Cholesterol, LDL; Drug Therapy, C | 2005 |
Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease.
Topics: Adult; Alkaline Phosphatase; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Di | 2006 |
Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease.
Topics: Adolescent; Adult; Aged; Bone Density Conservation Agents; Bone Diseases, Metabolic; Dose-Response R | 2007 |
Weekly risedronate in kidney transplant patients with osteopenia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Bone Density; Bone Density Conservation Agents; Bone | 2007 |
Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass.
Topics: Aged; Biomarkers; Bone Density; Bone Diseases, Metabolic; Calcium Radioisotopes; Diphosphonates; Eti | 2007 |
Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass.
Topics: Aged; Biomarkers; Bone Density; Bone Diseases, Metabolic; Calcium Radioisotopes; Diphosphonates; Eti | 2007 |
Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass.
Topics: Aged; Biomarkers; Bone Density; Bone Diseases, Metabolic; Calcium Radioisotopes; Diphosphonates; Eti | 2007 |
Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass.
Topics: Aged; Biomarkers; Bone Density; Bone Diseases, Metabolic; Calcium Radioisotopes; Diphosphonates; Eti | 2007 |
Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia.
Topics: Aged; Algorithms; Biomarkers; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resor | 2008 |
37 other studies available for risedronic acid and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Denosumab; Di | 2023 |
Effects of the combined administration of risedronate and menatetrenone on bone loss induced by tacrolimus in rats.
Topics: Animals; Bone Density; Bone Diseases, Metabolic; Drug Therapy, Combination; Femur; Immunosuppressive | 2020 |
Weekly oral bisphosphonates over 2 years prevent bone loss in cardiac transplant patients.
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Female; Fol | 2017 |
Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Dis | 2013 |
What is the role for bisphosphonates in IBD?
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Crohn Disease; Dietary Suppleme | 2014 |
Effect of risedronate in osteoporotic HIV males, according to gonadal status: a pilot study.
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Chol | 2014 |
Effect of Combined Teriparatide and Monthly Risedronate Therapy on Cancellous Bone Mass in Orchidectomized Rats: A Bone Histomorphometry Study.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; | 2015 |
Comparison of treatment effects of teriparatide and the bisphosphonate risedronate in an aged, osteopenic, ovariectomized rat model under various clinical conditions.
Topics: Aging; Animals; Bone Diseases, Metabolic; Disease Models, Animal; Female; Lumbar Vertebrae; Ovariect | 2016 |
Effects of swimming associated with risedronate in osteopenic bones: An experimental study with ovariectomized rats.
Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Bone Diseases, Met | 2015 |
Clinical and radiographic evaluation of effect of risedronate 5 mg as an adjunct to treatment of chronic periodontitis in postmenopausal women (12-month study).
Topics: Bone Density; Bone Diseases, Metabolic; Chronic Periodontitis; Dental Scaling; Female; Follow-Up Stu | 2016 |
Evaluation by digital subtraction radiography of induced changes in the bone density of the female rat mandible.
Topics: Animals; Anti-Inflammatory Agents; Bone Density; Bone Density Conservation Agents; Bone Diseases, Me | 2008 |
Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bo | 2009 |
Effects of the bisphosphonate risedronate on osteopenia in OASIS-deficient mice.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Cyclic AMP Resp | 2010 |
How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conser | 2010 |
Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Age | 2012 |
Risedronate improves bone mineral density in Crohn's disease: a complementary mechanism.
Topics: Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Crohn Disease; Etidronic A | 2012 |
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
Topics: Absorptiometry, Photon; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Densit | 2012 |
Osteoporosis, osteopenia and fracture risk: widening the therapeutic horizons.
Topics: Adult; Age Factors; Aged; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Diseases, | 2012 |
Comparative effects of risedronate and calcitriol on cancellous bone in rats with glucocorticoid-induced osteopenia.
Topics: Animals; Biomechanical Phenomena; Body Weight; Bone and Bones; Bone Density; Bone Diseases, Metaboli | 2006 |
Therapeutic effect of risedronate on cancellous and cortical bone in ovariectomized osteopenic rats: a comparison with the effects of alfacalcidol.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Disease Models, | 2006 |
Preventive effects of risedronate and calcitriol on cancellous osteopenia in rats treated with high-dose glucocorticoid.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption | 2006 |
Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats.
Topics: Absorptiometry, Photon; Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Meta | 2006 |
Beneficial effect of pretreatment and treatment continuation with risedronate and vitamin K2 on cancellous bone loss after ovariectomy in rats: a bone histomorphometry study.
Topics: Absorptiometry, Photon; Analysis of Variance; Animals; Body Weight; Bone Density; Bone Density Conse | 2006 |
Effects of risedronate on fracture risk in postmenopausal women with osteopenia.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Eti | 2008 |
Effects of risedronate in a rat model of osteopenia due to orchidectomy and disuse: densitometric, histomorphometric and microtomographic studies.
Topics: Absorptiometry, Photon; Animals; Body Composition; Bone and Bones; Bone Density; Bone Diseases, Meta | 2008 |
Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Cons | 2008 |
Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats.
Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcitoni | 1995 |
The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site.
Topics: Administration, Oral; Animals; Bone Density; Bone Development; Bone Diseases, Metabolic; Bone Remode | 1995 |
The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength--assessed in a sexually mature, ovariectomized rat model.
Topics: Analysis of Variance; Animals; Biomechanical Phenomena; Bone Density; Bone Diseases, Metabolic; Bone | 1995 |
Skeletal effects of withdrawal of estrogen and diphosphonate treatment in ovariectomized rats.
Topics: Animals; Bone and Bones; Bone Diseases, Metabolic; Disease Models, Animal; Estradiol; Etidronic Acid | 1993 |
Co-treatment of PGE2 and risedronate is better than PGE2 alone in the long-term treatment of ovariectomized-induced osteopenic rats.
Topics: Aging; Animals; Body Weight; Bone Development; Bone Diseases, Metabolic; Dinoprostone; Drug Therapy, | 1995 |
Risedronate plus prostaglandin E2 is superior to prostaglandin E2 alone in maintaining the added bone after withdrawal in a non-growing bone site in ovariectomized rats.
Topics: Analysis of Variance; Animals; Bone Diseases, Metabolic; Dinoprostone; Disease Models, Animal; Drug | 1995 |
Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats.
Topics: Animals; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcitonin; Disease Models, Animal | 1995 |
No loss of biomechanical effects after withdrawal of short-term PTH treatment in an aged, osteopenic, ovariectomized rat model.
Topics: Aging; Animals; Biomechanical Phenomena; Bone and Bones; Bone Diseases, Metabolic; Calcium Channel B | 1997 |
Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1-84)]-treated rats by estrogen, risedronate, or reduced hPTH.
Topics: Animals; Bone Density; Bone Diseases, Metabolic; Calcium Channel Blockers; Diphosphonates; Estrogens | 2001 |
Sequential treatment with basic fibroblast growth factor and PTH is more efficacious than treatment with PTH alone for increasing vertebral bone mass and strength in osteopenic ovariectomized rats.
Topics: Aging; Animals; Biomechanical Phenomena; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Ca | 2002 |
Restoring and maintaining bone in osteopenic female rat skeleton: I. Changes in bone mass and structure.
Topics: Aging; Animals; Body Weight; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Resorption | 1992 |